Revelation Biosciences Files 8-K on Redeemable Warrants
Ticker: REVBW · Form: 8-K · Filed: Mar 17, 2025 · CIK: 1810560
| Field | Detail |
|---|---|
| Company | Revelation Biosciences, Inc. (REVBW) |
| Form Type | 8-K |
| Filed Date | Mar 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: warrants, disclosure, company-name-change
Related Tickers: REVB
TL;DR
REVB warrants are still active, exercisable for tiny fractions of stock at a near-zero price.
AI Summary
On March 17, 2025, Revelation Biosciences, Inc. filed an 8-K report. The filing indicates that the company's redeemable warrants, each exercisable for 1/16800th of a share of common stock at an exercise price of $0.00000001932 per share, are a subject of this report. The company was formerly known as Petra Acquisition Inc. and changed its name on April 23, 2020.
Why It Matters
This filing provides an update on the company's outstanding warrants, which could impact future share dilution and investor equity.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of warrant information and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 1/16800 — Share Fraction per Warrant (Indicates the very small portion of a share each warrant represents.)
- $0.00000001932 — Warrant Exercise Price (Extremely low exercise price for the warrants.)
Key Players & Entities
- Revelation Biosciences, Inc. (company) — Registrant
- March 17, 2025 (date) — Date of Report
- Petra Acquisition Inc. (company) — Former Company Name
- April 23, 2020 (date) — Date of Name Change
- 0.00000001932 (dollar_amount) — Exercise Price per Share
FAQ
What is the total number of redeemable warrants outstanding?
The filing does not specify the total number of redeemable warrants outstanding.
What is the expiration date of these redeemable warrants?
The filing does not state the expiration date of the redeemable warrants.
Are there any conditions attached to the exercise of these warrants?
The filing mentions that each warrant is exercisable for a fraction of a share at a specific price, but does not detail other conditions.
What is the purpose of this 8-K filing regarding the warrants?
The filing is a current report indicating information about the company's redeemable warrants, as per SEC regulations.
Does the low exercise price suggest potential for significant dilution?
While the exercise price is extremely low, the impact on dilution depends on the number of warrants outstanding and the company's stock price performance.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding REVELATION BIOSCIENCES, INC. (REVBW).